✦ LIBER ✦

Endovascular brachytherapy: The FDA's perspective

✍ Scribed by Tara A. Ryan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FDA’S Perspectives on Cardiovascular Dev

✍ Eric A. Chen; Sonna M. Patel-Raman; Kathryn O’Callaghan; Matthew G. Hillebrenner 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 89 KB

Toxicity Testing: The FDA Perspective

✍ JANE E. HENNEY 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

The american brachytherapy society persp

✍ Subir Nag; Patricia E Cole; Ian Crocker; Shirish K Jani; K.V Krishnasastry; Vinc 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 105 KB

VARC Consensus Report: The FDA Perspecti

✍ Matthew G. Hillebrenner; Julie A. Swain; Bram Zuckerman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Endovascular brachytherapy in coronary a

✍ V.L.M.A Coen; A.H.M Knook; A.J Wardeh; W.J van der Giessen; C De Pan; D Sipkema; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 348 KB

Endovascular brachytherapy in the preven

✍ Josef Dvořák; Jan Fridrich; Jan Raupach; Jiřı́ Petera; Antonı́n Krajina; Milosla 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 114 KB